-
Study aim
-
Determination of the effect of 5% minoxidil and topical epinephrine solution on the interval between chemotherapy-induced hair loss hair regrowth, duration of hair loss, and prevention of hair loss
Comparison of the efficacy of 5% minoxidil, topical epinephrine, and placebo on the interval to chemotherapy-induced hair loss
-
Design
-
Participants will randomly be divided into three groups of 21 patients using a statistical software. All three groups will be matched for age, sex, and other demographic characteristics.This phase-3 study is a parallel group, double blind, randomized controlled trial.
-
Settings and conduct
-
Eligible patients will receive the drugs 1 hour before, during, and 1 month after chemotherapy. They will be examined every 2-3 weeks and trichoscopy will be performed using the FotoFinder at the beginning, the second or third time, the last time, and 1 month after chemotherapy.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Patients with breast cancer referred to Shohadaye Tajrish Hospital for chemotherapy including adriamycin, cyclophosphamide, and taxol in 2020-2021, informed consent to participate in the study.
Exclusion criteria: Presence of metastasis or inflammatory scalp disease, other causes of hair loss such as telogen effluvium, lichen planopilaris, discoid lupus erythematosus, and pregnant or lactating women
-
Intervention groups
-
Participants will randomly be divided into three groups of 21 patients using a statistical software. One group will receive 5% minoxidil, the second group will receive 5 micro gram topical epinephrine, and the third group will receive placebo (1 ml alcohol) twice a day.
-
Main outcome variables
-
age, gender, duration of chemotherapy, doses of drugs, efficacy of drugs, severity of drug complications, marital status, education, occupation, presence of metastasis